LAKE ZURICH, Ill.–(BUSINESS WIRE)–#CommittedToLife–Fresenius Kabi, part of the healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has been certified by the Top Employers Institute as a 2026 Top Employer in the United States and North America. This affirms the company’s ongoing commitment to creating a positive work environment.
Globally, Fresenius Kabi was certified as a Top Employer for 2026 in 13 countries and two regions. Since 2023, Fresenius Kabi has achieved this prestigious recognition in several countries worldwide.
“This recurring milestone—our fourth consecutive certification in the U.S.—marks a pivotal step in building an exceptional workplace where every individual can succeed, today and in the years ahead,” said Deb Browne, head of Human Resources, Fresenius Kabi USA.
Top Employers Institute offers HR certification, benchmarking, and advisory. Its Program certifies organizations based on the results of its HR Best Practices Survey which covers several areas, including people strategy, work environment, talent acquisition, learning, inclusion, and wellbeing. In 2025, Top Employers Institute certified nearly 2,500 organizations in 131 countries/regions. These certified Top Employers positively impact the lives of more than 14 million employees globally.
“Achieving a Country Top Employer Certification for 2026 reflects Fresenius Kabi’s dedication to building an outstanding workplace that enables sustained business performance,” said Top Employers Institute CEO Adrian Seligman. “Their strong alignment between people strategy and organizational goals, combined with a commitment to continuous improvement, demonstrates the impact of their transformative practices. We are proud to recognize Fresenius Kabi for their meaningful contribution to a better world of work in the United States.”
To learn about U.S. career opportunities at Fresenius Kabi, visit www.fresenius-kabi.com/us/join-us.
About Fresenius Kabi
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies.
In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care.
Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare.
Fresenius Kabi is part of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale.
For more information, please visit www.fresenius-kabi.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release.
Management Board: Pierluigi Antonelli (Chairman), Marc Crouton, Andreas Duenkel, Dr. Christian Hauer,
Dr. Marc-Alexander Mahl, Dr. Sang-Jin Pak
Chairman of the Supervisory Board: Michael Sen
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg – HRB 11654
Contacts
Joanie Clougherty
Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, Illinois 60047
www.fresenius-kabi.com/us
[email protected]
